Mulders PF - Search Results

1

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA. Van Neste L, et al. Among authors: mulders pf. Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20. Eur Urol. 2016. PMID: 27108162

2

Value of biochemical markers in the management of disseminated prostatic cancer.

Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM. Mulders PF, et al. Eur Urol. 1992;21(1):2-5. doi: 10.1159/000474790. Eur Urol. 1992. PMID: 1376692

3

Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: mulders pf. Investig Urol (Berl). 1994;5:60-5. Investig Urol (Berl). 1994. PMID: 7719322 No abstract available.

4

Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma.

van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: mulders pf. Anal Cell Pathol. 1994 Aug;7(2):153-70. Anal Cell Pathol. 1994. PMID: 7993825

5

Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: mulders pf. Cancer. 1993 Nov 1;72(9):2667-74. doi: 10.1002/1097-0142(19931101)72:9<2667::aid-cncr2820720924>3.0.co;2-0. Cancer. 1993. PMID: 8402488

6

Treatment of advanced prostate cancer: the vaccine approach.

Mulders PF. Mulders PF. Scand J Urol Nephrol Suppl. 1999;203:41-3. doi: 10.1080/00365599950510049. Scand J Urol Nephrol Suppl. 1999. PMID: 10636569 No abstract available.

7

Immunotherapy for renal cell carcinoma.

Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Bleumer I, et al. Among authors: mulders pf. Eur Urol. 2003 Jul;44(1):65-75. doi: 10.1016/s0302-2838(03)00191-x. Eur Urol. 2003. PMID: 12814677 Review.

8

Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging.

Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO. Deserno WM, et al. Among authors: mulders pf. Radiology. 2004 Nov;233(2):449-56. doi: 10.1148/radiol.2332031111. Epub 2004 Sep 16. Radiology. 2004. PMID: 15375228

9

Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.

van Gils MP, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. van Gils MP, et al. Among authors: mulders pf. Eur Urol. 2005 Dec;48(6):1031-41. doi: 10.1016/j.eururo.2005.06.009. Epub 2005 Jul 1. Eur Urol. 2005. PMID: 16054748 Review.

10

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. Bleumer I, et al. Among authors: mulders pf. J Urol. 2006 Jan;175(1):57-62. doi: 10.1016/S0022-5347(05)00040-6. J Urol. 2006. PMID: 16406869 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters